Key Highlights:
- Massive Bio showcases AI-powered trial matching and real-world data solutions at ASCO25, impacting over 3,800 patients.
- Co-founder Dr. Arturo Loaiza-Bonilla delivers landmark presentations on AI’s role in reshaping cancer research and care.
- The company’s DUO platform and presence at ASCO Innovation Hub mark a significant step toward democratizing precision oncology.
Revolutionizing Cancer Care With Multi-Agent AI at ASCO25
Massive Bio is presenting its cutting-edge AI technology at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, aimed at transforming how cancer patients access clinical trials. The company’s proprietary multi-agent AI platform enables real-time, personalized matching of patients to oncology trials using advanced algorithms and an oncology-specific knowledge graph. The solution was prospectively validated in 3,800 patients, proving its clinical impact.
How Massive Bio Uses Real-World Data to Transform Oncology Insights
Through its DUO platform, Massive Bio combines real-world data with AI to enhance provider engagement and analytics in oncology care. Attendees at ASCO25 are being introduced to the platform’s ability to break down healthcare silos and deliver data-driven treatment insights, empowering both clinicians and researchers.
Leadership-Driven Innovation: Presentations by Co-Founders at ASCO25
The company’s leadership is deeply involved in shaping the AI-oncology dialogue. Co-founder Dr. Arturo Loaiza-Bonilla is delivering two presentations, including a poster on AI-powered trial matching and a joint ASCO/ESMO session on digital pre-screening hubs. His recent publication in NEJM AI explores “collaborative intelligence” in healthcare, a cornerstone of Massive Bio’s mission.
Strategic Global Vision and Cross-Sector Collaborations
As a founding member of the CancerX public-private partnership and participant in the White House’s Cancer Moonshot initiative, Massive Bio’s work spans 17 countries with a global team of over 100 experts. The company is actively partnering with pharma, CROs, and healthcare institutions to streamline the drug development lifecycle using AI.
By